MiR-217 inhibits clear cell renal cell carcinoma, hepatocellular carcinoma, gastric cancer and glioma by targeting E2F3, EZH2 and Runx2, respectively [24–27]. Here, E2F3 is linked to hepatocellular carcinoma.